Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05856760 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
A Phase 2 study of Immunoglobulin A Nephropathy, sponsored by Travere Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 20
- Study locations
NCT05856760: Completed Phase 2 study of Immunoglobulin A Nephropathy, sponsored by Travere Therapeutics.
NCT05856760 is a Phase 2 study of Immunoglobulin A Nephropathy that has completed, run by Travere Therapeutics. The registered enrollment target is 48 participants, below the 301-participant average among 13 other Immunoglobulin A Nephropathy trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05856760, a Phase 2 study of Immunoglobulin A Nephropathy, has completed, sponsored by Travere Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 20
- Study locations
Study Summary
This was a 28-week, open-label, multicenter, single-group Phase 2 exploratory study to determine the safety and effect of sparsentan in participants with IgAN who are at risk of disease progression to kidney failure despite being on both stable RAASi and SGLT2 inhibitor treatment for at least 12 weeks prior to study entry
Primary Outcome
The change from baseline in UA/C at Week 24 based on first morning void (FMV) samples
Conditions Studied
Interventions
- DRUG Sparsentan
Study Locations (20)
California
- Travere Investigational Site - Chula Vista
- Travere Investigational Site - Garden Grove
- Travere Investigational Site - Glendale
Idaho
- Travere Investigational Site - Boise
- Travere Investigational Site - Chubbuck
- Travere Investigational Site - Idaho Falls
New York
- Travere Investigation Site - Clifton Park
- Travere Investigational Site - Fresh Meadows
- Travere Investigational Site - New York
Illinois
- Travere Investigational Site - Chicago
- Travere Investigational Site - Evergreen Park
North Carolina
- Travere Investigational Site - Jacksonville
- Travere Investigational Site - New Bern
Alabama
- Travere Investigational Site - Birmingham
Colorado
- Travere Investigational Site - Denver
Indiana
- Travere Investigational Site - Fort Wayne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2023-05-19 |
| Est. Completion | 2024-10-25 |
| Phase | Phase 2 |
What the finished NCT05856760 record still lists
NCT05856760 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 301-participant average among 13 other Immunoglobulin A Nephropathy trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Immunoglobulin A Nephropathy appearing as the primary indexed condition, and to 1 intervention - of which Sparsentan is the first listed.
NCT05856760 names 20 study sites across 12 states, led by California, Idaho, New York.
Frequently Asked Questions
What is clinical trial NCT05856760 about?
NCT05856760 is a clinical study titled "A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN". This was a 28-week, open-label, multicenter, single-group Phase 2 exploratory study to determine the safety and effect of sparsentan in participants with IgAN who are at risk of disease progression to kidney failure despite being on both stable RAASi and SGLT2 inhibitor treatment for at least 12 wee...
What is the current status of trial NCT05856760?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2023-05-19. Estimated completion is 2024-10-25.
What conditions does trial NCT05856760 study?
This clinical trial studies the following conditions: Immunoglobulin A Nephropathy.
What interventions are being tested in trial NCT05856760?
The interventions under investigation include: Sparsentan (DRUG).
Who is sponsoring clinical trial NCT05856760?
This trial is sponsored by Travere Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05856760 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immunoglobulin A Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05856760's enrollment target sits among peer trials
48 12th of 13 higher than 2 of 13 other Immunoglobulin A Nephropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Immunoglobulin A Nephropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
RECRUITING · Phase 2
-
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
RECRUITING · Phase 2
-
Atrasentan in Patients With Proteinuric Glomerular Diseases
ACTIVE NOT RECRUITING · Phase 2
-
A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
RECRUITING
-
Study of Ravulizumab in Pediatric Participants With Primary IgAN
RECRUITING · Phase 3
-
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI